Ankylosing Spondylitis Market by Drug, Type of Molecule, Mechanism Of Action, Route Of Administration, Dosage Forms, End User

KEY MARKET STATISTICS
Base Year [2023]	USD 5.18 billion
Estimated Year [2024]	USD 5.60 billion
Forecast Year [2030]	USD 9.06 billion
CAGR (%)	8.31%

The FPNV Positioning Matrix is pivotal in evaluating the Ankylosing Spondylitis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Ankylosing Spondylitis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Ankylosing Spondylitis Market, highlighting leading vendors and their innovative profiles. These include Biothera Pharmaceuticals, Inc. by HiberCell, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Celltrion Healthcare Co.,Ltd., Eisai Co., Ltd, Eli Lilly and Company, Hetero Drugs Limited, Novartis AG, Reliance Life Sciences, Samsung Bioepis Co., Ltd., Sandoz International GmbH, Sanofi-Aventis Groupe S.A., Shanghai Pharmaceuticals Holding Co., Ltd., Trinity Biotech PLC, and Xian Janssen Pharmaceutical Ltd.

Market Segmentation & Coverage

This research report categorizes the Ankylosing Spondylitis Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug
- Cimzia
- Cosentyx
- Enbrel
- Humira
- Remicade
- Simponi
Type of Molecule
- Biologics
- Small Molecules
Mechanism Of Action
- Cyclooxygenase Inhibitors
- Tumor Necrosis Factor Inhibitors
Route Of Administration
- Oral
- Parenteral
Dosage Forms
- Liquid
- Solid
End User
- Clinics
- Hospitals
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Ankylosing Spondylitis Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Ankylosing Spondylitis Market?

3. What are the technology trends and regulatory frameworks in the Ankylosing Spondylitis Market?

4. What is the market share of the leading vendors in the Ankylosing Spondylitis Market?

5. Which modes and strategic moves are suitable for entering the Ankylosing Spondylitis Market?

Product Code: MRR-A339DAEFAAAE

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Ankylosing Spondylitis Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing incidences of ankylosing spondylitis
  - 5.1.1.2. Growing awareness about diagnostics and treatments for the disease
  - 5.1.1.3. Rising number of orthopedic hospitals and diagnostic centers
- 5.1.2. Restraints
  - 5.1.2.1. High cost of treatment and dearth of skilled surgeons and physiotherapists
- 5.1.3. Opportunities
  - 5.1.3.1. Acceleration in research and development expenditure for the treatment of the spondylitis
  - 5.1.3.2. The emergence of biologics for treating ankylosing spondylitis
- 5.1.4. Challenges
  - 5.1.4.1. Concerns related to patent expiration of already approved drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Ankylosing Spondylitis Market, by Drug

6.1. Introduction
6.2. Cimzia
6.3. Cosentyx
6.4. Enbrel
6.5. Humira
6.6. Remicade
6.7. Simponi

7. Ankylosing Spondylitis Market, by Type of Molecule

7.1. Introduction
7.2. Biologics
7.3. Small Molecules

8. Ankylosing Spondylitis Market, by Mechanism Of Action

8.1. Introduction
8.2. Cyclooxygenase Inhibitors
8.3. Tumor Necrosis Factor Inhibitors

9. Ankylosing Spondylitis Market, by Route Of Administration

9.1. Introduction
9.2. Oral
9.3. Parenteral

10. Ankylosing Spondylitis Market, by Dosage Forms

10.1. Introduction
10.2. Liquid
10.3. Solid

11. Ankylosing Spondylitis Market, by End User

11.1. Introduction
11.2. Clinics
11.3. Hospitals

12. Americas Ankylosing Spondylitis Market

12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Ankylosing Spondylitis Market

13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam

14. Europe, Middle East & Africa Ankylosing Spondylitis Market

14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom

15. Competitive Landscape

15.1. FPNV Positioning Matrix
15.2. Market Share Analysis, By Key Player
15.3. Competitive Scenario Analysis, By Key Player

16. Competitive Portfolio

16.1. Key Company Profiles
- 16.1.1. Biothera Pharmaceuticals, Inc. by HiberCell, Inc.
- 16.1.2. Boehringer Ingelheim International GmbH
- 16.1.3. Bristol-Myers Squibb
- 16.1.4. Celltrion Healthcare Co.,Ltd.
- 16.1.5. Eisai Co., Ltd
- 16.1.6. Eli Lilly and Company
- 16.1.7. Hetero Drugs Limited
- 16.1.8. Novartis AG
- 16.1.9. Reliance Life Sciences
- 16.1.10. Samsung Bioepis Co., Ltd.
- 16.1.11. Sandoz International GmbH
- 16.1.12. Sanofi-Aventis Groupe S.A.
- 16.1.13. Shanghai Pharmaceuticals Holding Co., Ltd.
- 16.1.14. Trinity Biotech PLC
- 16.1.15. Xian Janssen Pharmaceutical Ltd
16.2. Key Product Portfolio

17. Appendix

17.1. Discussion Guide
17.2. License & Pricing